Recent Finacing
Recent Raise
Arcellx is a clinical-stage biopharmaceutical company developing ARC-SparX modular cell therapies that combine ARC-T universal-receptor T cells with sparX soluble adaptor proteins to target BCMA and CD123 tumor antigens.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Arcellx.
